Frederic Levine, MD
Urology · Willoughby, OHNPI 1043205867
Payments from drug & device makers
Across 414 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$956
- Sumitomo Pharma America, Inc.$789
- Dendreon Pharmaceuticals LLC$705
- AbbVie$640
- Tolmar, Inc.$466
- Bayer$428
- plus $4K from 32 others
What the payments were for
- Food & beverage$7,33596%
- Education$2704%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 58 | $956 |
| Sumitomo Pharma America, Inc. | 41 | $789 |
| Dendreon Pharmaceuticals LLC | 25 | $705 |
| AbbVie(2 entities) | 38 | $640 |
| Tolmar, Inc. | 46 | $466 |
| Bayer | 19 | $428 |
| C. R. Bard, Inc. & Subsidiaries | 7 | $385 |
| Johnson & Johnson | 14 | $319 |
| Endo Pharmaceuticals Inc. | 22 | $297 |
| Rochester Medical Corporation | 6 | $279 |
| Pfizer | 14 | $266 |
| Tolmar Pharmaceuticals, Inc. | 16 | $224 |
| Ferring Pharmaceuticals Inc. | 11 | $165 |
| Teleflex LLC | 8 | $159 |
| Boston Scientific | 7 | $151 |
| Antares Pharma, Inc. | 9 | $150 |
| Coloplast | 9 | $137 |
| AstraZeneca | 8 | $130 |
| Myovant Sciences Inc. | 8 | $118 |
| Urogen Pharma, Inc. | 7 | $103 |
| Merck | 4 | $70 |
| Blue Earth Diagnostics | 4 | $69 |
| Axonics, Inc. | 4 | $66 |
| Convatec Inc. | 3 | $63 |
| Progenics Pharmaceuticals, Inc. | 3 | $59 |
| Endo USA, Inc. | 3 | $48 |
| Dentsply IH Inc. | 3 | $47 |
| Sun Pharmaceutical Industries Inc. | 2 | $47 |
| Foundation Medicine, Inc. | 3 | $42 |
| Neotract Inc. | 2 | $37 |
| Metuchen Pharmaceuticals | 2 | $33 |
| Urovant Sciences Inc | 2 | $32 |
| Calyxo, Inc. | 1 | $25 |
| Accord Healthcare, Inc. | 1 | $23 |
| Novartis | 1 | $23 |
| Halozyme Inc | 1 | $20 |
| Telix Pharmaceuticals | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,606 in reported general payments places this provider in the 70th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 56 | $757,900 |
| OrgovyxRelugolix | 40 | $104,509 |
| MyrbetriqMirabegron | 66 | $64,084 |
| Tamsulosin Hcl | 730 | $9,807 |
| Finasteride | 309 | $3,821 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 80 | $1,873 |
| Cephalexin | 96 | $1,108 |
| Solifenacin Succinate | 29 | $1,079 |
| Oxybutynin Chloride ErOxybutynin Chloride | 36 | $1,076 |
| Doxazosin Mesylate | 24 | $659 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 56 | $613 |
| Oxybutynin Chloride | 18 | $532 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 24 | $525 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 106 | $516 |
| NitrofurantoinNitrofurantoin Macrocrystal | 17 | $230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $956 | $821,984122 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $789 | $104,50940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 485 urology providers in Ohio.
Other urology in Willoughby
- Marc PliskinCincinnati$20.8M
- Lawrence GervasiMiddleburg Heights$4.7M
- Martin FritzhandCincinnati$4.6M
- Kamal PoharCincinnati$3.4M
- Eric SingerColumbus$2.1M
- Benjamin MartinGahanna$1.1M
- Howard GoldmanCleveland$747K
- Jihad KaoukCleveland$696K
- Raymond RackleyCleveland$695K
- Sandip VasavadaCleveland$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.